{'52WeekChange': None,
 'SandP52WeekChange': None,
 'address1': 'Winzerlaer Str. 2',
 'algorithm': None,
 'annualHoldingsTurnover': None,
 'annualReportExpenseRatio': None,
 'ask': 4.78,
 'askSize': 800,
 'averageDailyVolume10Day': 1801700,
 'averageVolume': 1015317,
 'averageVolume10days': 1801700,
 'beta': 0.545998,
 'beta3Year': None,
 'bid': 4.7,
 'bidSize': 800,
 'bookValue': 7.198,
 'category': None,
 'circulatingSupply': None,
 'city': 'Jena',
 'companyOfficers': [],
 'country': 'Germany',
 'currency': 'USD',
 'dateShortInterest': 1593475200,
 'dayHigh': 4.85,
 'dayLow': 4.6003,
 'dividendRate': None,
 'dividendYield': None,
 'earningsQuarterlyGrowth': None,
 'enterpriseToEbitda': None,
 'enterpriseToRevenue': None,
 'enterpriseValue': 122694696,
 'exDividendDate': None,
 'exchange': 'NMS',
 'exchangeTimezoneName': 'America/New_York',
 'exchangeTimezoneShortName': 'EDT',
 'expireDate': None,
 'fiftyDayAverage': 5.45,
 'fiftyTwoWeekHigh': 9.698,
 'fiftyTwoWeekLow': 2.17,
 'fiveYearAverageReturn': None,
 'fiveYearAvgDividendYield': None,
 'floatShares': 15111810,
 'forwardEps': -1.42,
 'forwardPE': -3.309859,
 'fromCurrency': None,
 'fullTimeEmployees': 43,
 'fundFamily': None,
 'fundInceptionDate': None,
 'gmtOffSetMilliseconds': '-14400000',
 'headSymbol': None,
 'heldPercentInsiders': 0.3378,
 'heldPercentInstitutions': 0.20002002,
 'industry': 'Biotechnology',
 'isEsgPopulated': False,
 'lastCapGain': None,
 'lastDividendValue': None,
 'lastFiscalYearEnd': 1577750400,
 'lastMarket': None,
 'lastSplitDate': None,
 'lastSplitFactor': None,
 'legalType': None,
 'logo_url': 'https://logo.clearbit.com/inflarx.de',
 'longBusinessSummary': 'InflaRx N.V., a clinical-stage biopharmaceutical '
                        'company, discovers and develops inhibitors using C5a '
                        'technology primarily in the Germany and United '
                        'States. Its C5a is an inflammatory mediator that is '
                        'involved in the enhancement of a variety of '
                        'autoimmune and other inflammatory diseases. The '
                        "company's lead product candidate is IFX-1, an "
                        'intravenously delivered first-in-class anti-C5a '
                        'monoclonal antibody, which completed the Phase IIb '
                        'clinical trial for the treatment of hidradenitis '
                        'suppurativa, a rare and chronic debilitating systemic '
                        'inflammatory skin disease; to treat ANCA-associated '
                        'vasculitis, a rare and life-threatening autoimmune '
                        'disease; and for the treatment of pyoderma '
                        'gangrenosum, a chronic inflammatory skin disorder, as '
                        'well as developing IFX-1 for the treatment of '
                        'oncological diseases. It also develops IFX-2 that is '
                        'in pre-clinical development stage for the treatment '
                        'of chronic inflammation and autoimmune diseases. '
                        'InflaRx N.V. has co-development agreement with '
                        'Beijing Defengrei Biotechnology Co. Ltd. The company '
                        'was formerly known as Fireman B.V. and changed its '
                        'name to InflaRx N.V. in 2017. InflaRx N.V. was '
                        'founded in 2007 and is headquartered in Jena, '
                        'Germany.',
 'longName': 'InflaRx N.V.',
 'market': 'us_market',
 'marketCap': 123469936,
 'maxAge': 1,
 'maxSupply': None,
 'messageBoardId': 'finmb_42434000',
 'morningStarOverallRating': None,
 'morningStarRiskRating': None,
 'mostRecentQuarter': 1585612800,
 'navPrice': None,
 'netIncomeToCommon': None,
 'nextFiscalYearEnd': 1640908800,
 'open': 4.8,
 'openInterest': None,
 'payoutRatio': 0,
 'pegRatio': None,
 'phone': '49 3641 508 180',
 'previousClose': 4.91,
 'priceHint': 4,
 'priceToBook': 0.6529591,
 'priceToSalesTrailing12Months': None,
 'profitMargins': 0,
 'quoteType': 'EQUITY',
 'regularMarketDayHigh': 4.85,
 'regularMarketDayLow': 4.6003,
 'regularMarketOpen': 4.8,
 'regularMarketPreviousClose': 4.91,
 'regularMarketPrice': 4.8,
 'regularMarketVolume': 540862,
 'revenueQuarterlyGrowth': None,
 'sector': 'Healthcare',
 'sharesOutstanding': 26270200,
 'sharesPercentSharesOut': 0.026199998,
 'sharesShort': 684839,
 'sharesShortPreviousMonthDate': 1590710400,
 'sharesShortPriorMonth': 145642,
 'shortName': 'InflaRx N.V.',
 'shortPercentOfFloat': 0.0315,
 'shortRatio': 0.77,
 'startDate': None,
 'strikePrice': None,
 'symbol': 'IFRX',
 'threeYearAverageReturn': None,
 'totalAssets': None,
 'tradeable': False,
 'trailingAnnualDividendRate': None,
 'trailingAnnualDividendYield': None,
 'trailingEps': -1.387,
 'twoHundredDayAverage': 5.1191006,
 'underlyingExchangeSymbol': None,
 'underlyingSymbol': None,
 'uuid': 'd7dac691-49fb-3198-8a3e-7fa9a0420fa3',
 'volume': 540862,
 'volume24Hr': None,
 'volumeAllCurrencies': None,
 'website': 'http://www.inflarx.de',
 'yield': None,
 'ytdReturn': None,
 'zip': '07745'}